Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia

Schizophrenia Research

Volumn 91, Issue 1-3, 2007, Pages 178-186

  Wehmeier, Peter M ^a   Kluge, Michael ^b   Schacht, Alexander ^a   Helsberg, Karin ^a   Schreiber, Wolfgang ^c  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c Psychiatric Hospital   (Germany)

Author keywords

Antipsychotics; QLS; Quality of life; Schizophrenia; Subjective well being; SWN

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; COMPARATIVE STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATURALISTIC INQUIRY; OUTPATIENT; PHYSICIAN; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOTHERAPY; QUALITY OF LIFE; QUALITY OF LIFE INDEX; SCHIZOPHRENIA; SEX DIFFERENCE; SUBJECTIVE WELL BEING ON NEUROLEPTIC SCALE; WELLBEING;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; FEMALE; HUMANS; MALE; PATIENTS; PHYSICIANS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RISPERIDONE; SCHIZOPHRENIA; SELF CONCEPT;

EID: 33847281876     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.12.017     Document Type: Article

References (36)

1. Bobes J., García-Portilla P., Sáiz P.A., Bascarán T., and Bousoño M. Quality of life measures in schizophrenia. Eur. Psychiatr. 20 3 (2005) 313-317
2. Czernikiewicz A., and Gorecka J. Comparison of subjective and objective quality of life in a group of schizophrenic patients. Psychiatr. Pol. 37 4 (2003) 669-681
3. Concato J., Shah N., and Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342 25 (2000) 1887-1892
4. Cramer J.A., et al., for the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Quality of life in schizophrenia: A comparison of instruments. Schizophr. Bull. 26 3 (2000) 659-666
5. Csernansky J.G., and Schuchart E.K. Relapse and rehospitalization rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 6 7 (2002) 473-484
6. de Haan L., Weisfelt M., Dingemans P.M.A.J., Linszen D.H., and Wouters L. Psychometric properties of the subjective well-being under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology 162 1 (2002) 24-28
7. Dossenbach M., Arango-Davila C., Silva Ibarra H., Landa E., Aguilar J., Caro O., Leadbetter J., and Assuncao S. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the International Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J. Clin. Psychiatry 66 8 (2005) 1021-1030
8. Doyle M., Flanagan S., Browne S., Clarke M., Lydon D., Larkin C., and O'Callaghan E. Subjective and external assessments of quality of life in schizophrenia: relationship to insight. Acta Psychiatr. Scand. 99 6 (1999) 466-472
9. Fitzgerald P.B., Williams C.L., Corteling N., Filia S.L., Brewer K., Adams A., de Castella A.R., Rolfe T., Davey P., and Kulkarni J. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr. Scand. 103 5 (2001) 387-392
10. Gourevitch R., Abbadi S., and Guelfi J.D. Quality of life in schizophrenics with and without the deficit syndrome. Eur. Psychiatr. 19 3 (2004) 172-174
11. Gureje O., Miles W., Keks N., Grainger D., Lambert T., McGrath J., Tran P.V., Catts S., Fraser A., Hustig H., Andersen S., and Crawford A.M. Olanzapine vs. risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr. Res. 61 2-3 (2003) 303-314
12. Hamilton S.H., Edgell E.T., Revicki D.A., and Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int. J. Clin. Psychopharmacol. 15 5 (2000) 245-255
13. Heinrichs D.W., Hanlon T.E., and Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 10 3 (1984) 388-398
14. Hofer A., Kemmler G., Ederm U., Edlinger M., Hummer M., and Fleischhacker W.W. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J. Clin. Psychiatry 65 7 (2004) 932-939
15. Hofer A., Baumgartner S., Edlinger M., Hummer M., Kemmler G., Rettenbacher M.A., Schweigkofler H., Schwitzer J., and Fleischhacker W.W. Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. Eur. Psychiatr. 20 5-6 (2005) 386-394
16. Karow A., and Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 162 1 (2002) 3-10
17. Kilian R., Dietrich S., Toumi M., and Angermeyer M.C. Quality of life in persons with schizophrenia in out-patient treatment with first-or second-generation antipsychotics. Acta Psychiatr. Scand. 110 2 (2004) 108-118
18. Kluge M., Wehmeier P.M., Dittmann R.W., Langer F., Czekalla J., Lehmann M., Kessler F.H., Beyenburg S., and Naber D. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry 38 1 (2005) 6-12
19. Lysaker P.H., Buck K.D., Hammoud K., Taylor A.C., and Roe D. Associations of symptoms, psychosocial function and hope with qualities of self-experience in schizophrenia: comparisons of objective and subjective indicators of health. Schizophr. Res. 82 2-3 (2006) 241-249
20. Melle I., Friis S., Haahr U., Johannesen J.O., Larsen T.K., Opjordsmoen S., Roessberg J.I., Rund B.R., Simonsen E., Vaglum P., and McGlashan T. Measuring quality of life in first-episode psychosis. Eur. Psychiatr. 20 7 (2005) 474-483
21. Montes J.M., Ciudad A., Gascon J., Gomez J.C., and EFESO Study Group. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 4 (2003) 667-674
22. Naber D. A self-rating to measure subjective effects of neuroleptic drugs. Relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int. J. Clin. Psychopharmacol. 10 Suppl 3 (1995) 133-138
23. Naber D., Moritz S., Lambert M., Pajonk F.G., Holzbach R., Mass R., and Andresen B. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res. 50 1-2 (2001) 79-88
24. Naber D., Karow A., and Lambert M. Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatr. Scand., Suppl 427 (2005) 29-34
25. Naber D., Riedel M., Klimke A., Vorbach E.U., Lambert M., Kühn K.U., Bender S., Bandelow B., Lemmer W., Moritz S., and Dittmann R.W. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcomes in patients with schizophrenia. Acta Psychiatr. Scand. 111 2 (2005) 106-115
26. Norman R.M., Malla A.K., McLean T., Voruganti L.P., Cortese L., McIntosh E., Cheng S., and Rickwood A. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr. Scand. 102 4 (2000) 303-309
27. Revicki D.A., Genduso L.A., Hamilton S.H., Ganoczy D., and Beasley C.M. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual. Life Res. 8 5 (1999) 417-426
28. Ritsner M., Gibel A., Perelroyzen G., Kurs R., Jabarin M., and Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice. A naturalistic comparative study. J. Clin. Psychopharmacol. 24 6 (2004) 582-591
29. Roeder-Wanner U.U., and Priebe S. Objective and subjective quality of life of first-admitted women and men with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 248 5 (1998) 250-258
30. Silva de Lima M., de Jesus Mari J., Breier A., Costa A.M., Pondé de Sena E., and Hotopf M. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J. Clin. Psychiatry 66 7 (2005) 831-838
31. Tollefson G.D., Beasley C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., and Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 154 4 (1997) 457-465
32. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley C., and Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17 5 (1997) 407-418
33. Voruganti L., Cortese L., Oyewumi L., Cernovsky Z., Zirul S., and Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr. Res. 43 2-3 (2000) 135-145
34. Wehmeier, P.M., Kluge, M., Schneider, E., Schacht, A., Wagner, T., Schreiber, W., in press. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry.
35. Whitty P., Browne S., Clarke M., McTigue O., Waddington J., Kinsella T., Larkin C., and O'Callaghan E. Systematic comparison of subjective and objective measures of quality of life at 4-year follow-up subsequent to a first episode of psychosis. J. Nerv. Mental Dis. 192 12 (2004) 805-809
36. Zhang P.L., Santos J.M., Newcomer J., Pelfrey B.A., Johnson M.C., and de Erausquin G.A. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr. Res. 71 1 (2004) 137-144